Table 3.
Individual pathologic characteristics by region
| Total | Beijing (North) |
Liaoning (Northeast) |
Hunan (Central) |
Guangdong (South) |
Zhejiang (East) |
Shannxi (Northwest) |
Sichuan (Southwest) |
χ2 | P-value | |
|---|---|---|---|---|---|---|---|---|---|---|
| Pathological Characteristics | Total N = 4211 | Total N = 641 | Total N = 832 | Total N = 546 | Total N = 604 | Total N = 606 | Total N = 483 | Total N = 499 | ||
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |||
| Type of Postoperative Pathological Diagnosis(1) | ||||||||||
| Carcinoma in Situ (CIS) | 143 (3.4) | 61 (9.5) | 22 (2.6) | 17 (3.1) | 19 (3.1) | 7 (1.2) | 5 (1.0) | 12 (2.4) | 169.1 | < 0.001 |
| Invasive Ductal Carcinoma | 3471 (82.4) | 528 (82.4) | 583 (70.1) | 504 (92.4) | 528 (87.4) | 523 (86.3) | 406 (84.1) | 399 (80.0) | ||
| Other Invasive Carcinoma | 385 (9.1) | 47 (7.3) | 87 (10.5) | 21 (3.8) | 29 (4.8) | 59 (9.7) | 70 (14.5) | 72 (14.4) | ||
| Other | 15 (0.4) | 5 (0.8) | 0 (0.0) | 1 (0.2) | 4 (0.7) | 0 (0.0) | 2 (0.4) | 3 (0.6) | ||
| Unavailable | 197 (4.7) | - | 140 (16.8) | 3 (0.5) | 24 (4.0) | 17 (2.8) | - | 13 (2.6)) | ||
| Pathological stage(2) | ||||||||||
| Stage 0 | 39 (0.9) | 7 (1.1) | 13 (1.6) | 6 (1.1) | 8 (1.3) | 4 (0.7) | 0 (0.0) | 1 (0.2) | 450.5 | < 0.001 |
| Stage I | 663 (15.7) | 172 (26.8) | 131 (15.7) | 73 (13.4) | 98 (16.2) | 95 (15.7) | 77 (15.9) | 17 (3.4) | ||
| Stage II | 1891 (44.9) | 280 (43.7) | 323 (38.8) | 400 (73.3) | 243 (40.2) | 239 (39.4) | 170 (35.2) | 236 (47.3) | ||
| Stage III | 788 (18.7) | 93 (14.5) | 119 (14.3) | 53 (9.7) | 117 (19.4) | 152 (25.1) | 127 (26.3) | 127 (25.5) | ||
| Stage IV | 113 (2.7) | 2 (0.3) | 4 (0.5) | 3 (0.5) | 20 (3.4) | 5 (0.8) | 56 (11.6) | 23 (4.6) | ||
| Unavailable | 717 (17.1) | 87 (13.6) | 242 (29.1) | 11 (2.0) | 118 (19.5) | 111 (18.3) | 53 (11.0) | 95 (19.0) | ||
| ER/PR test | ||||||||||
| Performed | 3555 (84.4) | 616 (96.1) | 711 (85.5) | 535 (98.0) | 511 (84.6) | 462 (76.2) | 282 (58.4) | 438 (87.8) | 483.2 | < 0.001 |
| Not performed | 471 (11.2) | 24 (3.7) | 85 (10.2) | 8 (1.5) | 54 (8.9) | 67 (11.1) | 192 (39.8) | 41 (8.2) | ||
| Unknown | 185 (4.4) | 1 (0.2) | 36 (4.3) | 3 (0.5) | 39 (6.5) | 77 (12.7) | 9 (1.8) | 20 (4.0) | ||
| Her-2 test | ||||||||||
| Performed | 3251 (77.2) | 609 (95.0) | 693 (83.3) | 533 (97.6) | 469 (77.6) | 424 (70.0) | 241 (49.9) | 282 (56.5) | 640.2 | < 0.001 |
| Not performed | 762 (18.1) | 31 (4.8) | 98 (11.8) | 8 (1.5) | 99 (16.4) | 98 (16.1) | 227 (47.0) | 201 (40.3) | ||
| Unknown | 198 (4.7) | 1 (0.2) | 41 (4.9) | 5 (0.9) | 36 (6.0) | 84 (13.9) | 15 (3.1) | 16 (3.2) | ||
| ER/PR status(3) | ||||||||||
| ER+&PR+ | 1691 (47.6) | 373 (60.6) | 318 (44.7) | 244 (45.6) | 241 (47.2) | 221 (47.8) | 109 (38.7) | 185 (42.2) | 121.0 | < 0.001 |
| ER+&PR- | 337 (9.5) | 44 (7.1) | 79 (11.1) | 54 (10.1) | 37 (7.2) | 41 (8.9) | 31 (11.0) | 51 (11.6) | ||
| ER-&PR+ | 367 (10.3) | 47 (7.6) | 108 (15.2) | 32 (6.0) | 75 (14.7) | 34 (7.4) | 37 (13.1) | 34 (7.8) | ||
| ER-&PR- | 1139 (32.0) | 146 (23.7) | 206 (29.0) | 203 (37.9) | 152 (29.7) | 165 (35.7) | 101 (35.8) | 166 (37.9) | ||
| Unavailable | 21 (0.6) | 6 (1.0) | - | 2 (0.4) | 6 (1.2) | 1 (0.2) | 4 (1.4) | 2 (0.5) | ||
| Her-2 status(4) | ||||||||||
| Her-2 + | 736 (22.6) | 286 (47.0) | 36 (5.2) | 156 (29.3) | 90 (19.2) | 68 (16.0) | 29 (12.0) | 71 (25.2) | 339.6 | < 0.001 |
| Her-2 - | 2113 (65.0) | 299 (49.1) | 545 (78.6) | 314 (58.9) | 337 (71.9) | 317 (74.8) | 181 (75.1) | 120 (42.6) | ||
| Uncertain/unavailable | 402 (12.4) | 24 (3.9) | 112 (16.2) | 63(11.8) | 42 (9.1) | 39 (9.2) | 31 (12.9) | 91 (32.2) | ||
(1): carcinoma in situ: ductal carcinoma in situ, lobular carcinoma in situ, microinvasive ductal carcinoma, and Paget's disease invasive ductal carcinoma: pure invasive ductal carcinoma and mixed invasive ductal carcinoma other invasive carcinomas: invasive labular carcinoma, tubular carcinoma, medullary carcinoma, mucin carcinoma, and other invasive carcinomas
(2): according to the AJCC/UICC TNM system
(3): ER/PR status was based on all breast cancer cases tested for ER/PR
(4): Her-2 status was based on all breast cancer cases tested for Her-2